News

Home / News

Announcement of the Company's list of newly elected directors

2026.5.27

1.Date of occurrence of the change:2026/05/27

2.Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor):Institutional director、independent director and natural-person director

3.Title and name of the previous position holder:
(1)Director:Representative of TTY Biopharm Company Limited:Chuan Lin (2)Director:Representative of TTY Biopharm Company Limited:Carl Hsiao (3)Director:Representative of TTY Biopharm Company Limited:Kang-Chi Chou (4)Director:Representative of TTY Biopharm Company Limited:Yong-Liang Wu (5)Independent Director:Te-Yu Chou (6)Independent Director:Rwei-Syun Chen (7)Independent Director:Yaw-Bin Huang (8)Independent Director:Shiow-Ming Wu (9)Independent Director:Yuen-Liang Lai
4.Resume of the previous position holder:
(1)Chuan Lin:Chairman of TTY Biopharm Company Limited (2)Carl Hsiao:Director of TTY Biopharm Company Limited (3)Kang-Chi Chou:Chairman of BaaS Innovation Co., Ltd. (4)Yong-Liang Wu:Supervisor of Dawan Technology Co., Ltd. (5)Te-Yu Chou:Independent Director of Taiwan Cooperative Bank (6)Rwei-Syun Chen:Independent Director of GENERAL BIOLOGICALS CORP. (7)Yaw-Bin Huang:Professor of School of Pharmacy, Kaohsiung Medical University (8)Shiow-Ming Wu:Adjunct Professor of Department of Land Economics, National Chengchi University (9)Yuen-Liang Lai:Honorary Consultant Physician, MacKay Memorial Hospital
5.Title and name of the new position holder:
(1)Director:Representative of TTY Biopharm Company Limited:Chuan Lin (2)Director:Representative of TTY Biopharm Company Limited:Carl Hsiao (3)Director:Representative of TTY Biopharm Company Limited:Kang-Chi Chou (4)Director:Duei Tsai (5)Director:Representative of TTY Biopharm Company Limited:Yong-Liang Wu (6)Independent Director:Yaw-Bin Huang (7)Independent Director:Te-Yu Chou (8)Independent Director:Shiow-Ming Wu (9)Independent Director:Yuen-Liang La
6.Resume of the new position holder:
(1)Chuan Lin:Chairman of TTY Biopharm Company Limited (2)Carl Hsiao:Director of TTY Biopharm Company Limited (3)Kang-Chi Chou:Chairman of BaaS Innovation Co., Ltd. (4)Duei Tsai:Independent Director of Taiwan High Speed Rail Corporation (5)Yong-Liang Wu:Supervisor of Dawan Technology Co., Ltd. (6)Yaw-Bin Huang:Professor of School of Pharmacy, Kaohsiung Medical University (7)Te-Yu Chou:Independent Director of Taiwan Cooperative Bank (8)Shiow-Ming Wu:Adjunct Professor of Department of Land Economics, National Chengchi University (9)Yuen-Liang Lai:Honorary Consultant Physician, MacKay Memorial Hospital
7.Circumstances of change (Please enter “resignation”, “dismissal”,“term expired”, “death” or “new appointment”): Term expired

8.Reason for the change:Re-election of the Board of Directors

9.Number of shares held by the new position holder when elected:
(1)Director:TTY Biopharm Company Limited(Representative:Chuan Lin); 21,687,177 shares (2)Director:TTY Biopharm Company Limited(Representative:Carl Hsiao); 21,687,177 shares (3)Director:TTY Biopharm Company Limited(Representative:Kang-Chi Chou); 21,687,177 shares (4)Director:Duei Tsai;0 shares (5)Director:TTY Biopharm Company Limited(Representative:Yong-Liang Wu); 21,687,177 shares (6)Independent Director:Yaw-Bin Huang;0 shares (7)Independent Director:Te-Yu Chou;0 shares (8)Independent Director:Shiow-Ming Wu;0 shares (9)Independent Director:Yuen-Liang Lai;0 shares
10.Original term (from __________ to __________):2023/05/25~2026/05/24

11.Effective date of the new appointment:2026/05/27

12.Turnover rate of directors of the same term:NA

13.Turnover rate of independent directors of the same term:NA

14.Turnover rate of supervisors of the same term:NA

15.Change in one-third or more of directors (Please enter “Yes” or“No”):NA

16.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 6 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None